Chemistry:Mezigdomide
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C32H30FN5O4 |
| Molar mass | 567.621 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mezigdomide is a cereblon E3 ligase modulator developed by Bristol Myers Squibb to treat multiple myeloma.[1][2][3][4][5]
References
- ↑ Richardson, Paul G.; Trudel, Suzanne; Quach, Hang; Popat, Rakesh; Lonial, Sagar; Orlowski, Robert Z.; Kim, Kihyun; Mateos, María-Victoria et al. (15 November 2022). "Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial". Blood 140 (Supplement 1): 1366–1368. doi:10.1182/blood-2022-157945.
- ↑ Gaffney, Bonny; Shi, Yu; de Jong, Petrus; Sanchez, Manuel; Fontanillo, Celia; Lopez-Girona, Antonia; Boss, Isaac W.; Kurtova, Antonina et al. (15 November 2022). "Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing". Blood 140 (Supplement 1): 7108–7109. doi:10.1182/blood-2022-157939.
- ↑ Richardson, Paul G.; Trudel, Suzanne; Popat, Rakesh; Mateos, María-Victoria; Vangsted, Annette J.; Ramasamy, Karthik; Martinez-Lopez, Joaquín; Quach, Hang et al. (14 September 2023). "Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma". New England Journal of Medicine 389 (11): 1009–1022. doi:10.1056/NEJMoa2303194. PMID 37646702.
- ↑ Midha, Shonali; Hartley-Brown, Monique A.; Mo, Clifton C.; Hossain, Shahrier; Nadeem, Omar; O’Donnell, Elizabeth K.; Bianchi, Giada; Sperling, Adam S. et al. (2 November 2023). "A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma". Expert Opinion on Drug Safety 22 (11): 1049–1071. doi:10.1080/14740338.2023.2274420. PMID 37906232.
- ↑ Richardson, Paul G; Mateos, María-Victoria; Vangsted, Annette J; Ramasamy, Karthik; Abildgaard, Niels; Ho, P Joy; Quach, Hang; Bahlis, Nizar J (3 June 2022). "The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease". Expert Review of Proteomics 19 (4–6): 235–246. doi:10.1080/14789450.2022.2142564. PMID 36342226.
 |  |
